> ## Content Index
> Fetch the complete content index at: https://www.whiteroseintelligence.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Alexion Pharmaceuticals
- URL: https://www.whiteroseintelligence.com/alexion-pharmaceuticals/
- Published: 1999-01-02T09:29:00.000Z
- Updated: 2025-04-11T01:41:45.000Z
- Author: Liam Sturgess
- Tags: Profiles, #docs, #organization

**Alexion Pharmaceuticals** is an American biopharmaceutical company based in Boston, Massachusetts. It is the rare disease division of [AstraZeneca](https://www.whiteroseintelligence.com/AstraZeneca).[\[1\]](#fn1)

## History

Alexion began collaborating with [Moderna](https://www.whiteroseintelligence.com/Moderna) in January 2014, entering an agreement for ten product options based on Moderna's mRNA platform.[\[2\]](#fn2)[\[3\]](#fn3) Alexion continued this work with Elpidera, a Moderna spinoff company launched in May 2015.[\[4\]](#fn4)

### COVID-19

The company had been running clinical trials on ULTOMIRIS (ravulizumab-cwvz) in hospitalized COVID-19 patients until they were paused in January 2021 due to lack of efficacy.[\[5\]](#fn5)

Alexion became the rare disease division of [AstraZeneca](https://www.whiteroseintelligence.com/AstraZeneca) after being acquired by the company in 2021.[\[1:1\]](#fn1)

## Activities

Alexion awarded a $200,000 Rare Belonging grant to Ronald McDonald House Charities in 2020.[\[6\]](#fn6)

## External links

- [Campfire Wiki](https://www.campfire.wiki/doku.php?id=pharmaceutical%5Fcompanies:alexion)
- [Wikipedia](https://en.wikipedia.org/wiki/Alexion%5FPharmaceuticals)

---

1. Kemp, A. (2021, July 21). *Acquisition of Alexion completed.* AstraZeneca. <http://archive.today/2021.12.19-065821/https://www.astrazeneca.com/media-centre/press-releases/2021/acquisition-of-alexion-completed.html> [↩︎](#fnref1) [↩︎](#fnref1:1)
2. *Elpidera.* Moderna Therapeutics. Retrieved October 12, 2016, from <http://archive.today/2016.10.12-231723/http://www.modernatx.com/our-business-model/ventures/elpidera> [↩︎](#fnref2)
3. Reidy, C. (2014, January 13). *Alexion, Moderna announce agreement to develop messenger RNA therapeutics.* Boston Globe Media Partners. <https://web.archive.org/web/20230605072835/https://www.boston.com/news/innovation/2014/01/13/alexion-moderna-announce-agreement-to-develop-messenger-rna-therapeutics/> [↩︎](#fnref3)
4. *Moderna Launches Third Venture Company Elpidera for Rare Diseases.* (2015, May 12). Moderna Therapeutics. <https://web.archive.org/web/20161012234942/http://www.modernatx.com/news-events/press-releases/moderna-launches-third-venture-company-elpidera-rare-diseases> [↩︎](#fnref4)
5. Goulart, M. (2021, January 13). *Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19.* Alexion Pharmaceuticals, Inc. <http://archive.today/2022.01.12-213352/https://ir.alexion.com/news-releases/news-release-details/alexion-provides-update-phase-3-study-ultomirisr-ravulizumab> [↩︎](#fnref5)
6. *Corporate Sponsors of RMHC.* Ronald McDonald House Charities. Retrieved January 17, 2022, from <http://archive.today/2022.01.13-065229/https://www.rmhc.org/about-us/our-partners> [↩︎](#fnref6)